Serum IGF1 on Female HFpEF Patients
Launched by THE UNIVERSITY OF HONG KONG-SHENZHEN HOSPITAL · Jun 3, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • age over 18;
- • female participants only;
- Exclusion Criteria:
- • with congenital heart disease or with other family disease history
- • participants receiving hormone therapy
About The University Of Hong Kong Shenzhen Hospital
The University of Hong Kong-Shenzhen Hospital (HKU-SZH) is a leading clinical research institution dedicated to advancing healthcare through innovative medical research and trials. Established as a collaboration between the University of Hong Kong and the Shenzhen municipal government, the hospital integrates clinical practice, education, and research, fostering a multidisciplinary approach to patient care. HKU-SZH is committed to enhancing medical knowledge and improving treatment outcomes by conducting rigorous clinical trials across various therapeutic areas. With a focus on ethical standards and patient welfare, the hospital aims to contribute to the global medical community through impactful research and collaboration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported